10-QPeriod: Q2 FY2024

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2024

Filed July 26, 2024For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending June 29, 2024, on July 25, 2024. While the filing provides detailed financial statements and management's discussion, it does not contain the actual financial performance figures (revenue, net income, etc.) in the provided snippet. Investors should refer to the full filing for specific performance metrics. The document outlines the structure of the report, indicating sections covering financial statements, management's discussion and analysis, market risk, legal proceedings, risk factors, and other information. Key areas to scrutinize in the full report will include the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" for insights into the company's performance drivers, challenges, and strategic outlook. Investors should pay close attention to Item 1A, "Risk Factors," as it will detail any new or evolving risks that could impact BMY's future financial performance. The report's structure suggests a comprehensive review of the company's operations and financial health. The absence of specific financial data in the provided excerpt means a deeper dive into the full 10-Q is essential for investors to understand the quarter's financial results, cash flow generation, and overall financial position.

Financial Highlights

56 data points
Beta

Revenue

$12.20B

73.2% Gross Margin

Net Income

$1.68B

13.8% Net Margin

EPS (Diluted)

$0.83

Total Assets

$94.65B

Cash & Equivalents

$6.30B

Free Cash Flow

$2.06B

Financial Statements
Beta
Revenue$12.20B
Cost of Revenue$3.27B
Gross Profit$8.93B
R&D Expenses$2.90B
SG&A Expenses$1.93B
Operating Expenses$10.91B
Net Income$1.68B
EPS (Basic)$0.83
EPS (Diluted)$0.83
Shares Outstanding (Basic)2.03B
Shares Outstanding (Diluted)2.03B

Key Highlights

  • 1The 10-Q filing covers the quarterly period ending June 29, 2024, and was filed on July 25, 2024.
  • 2The filing includes standard SEC disclosure sections: Financial Statements, Management's Discussion and Analysis, Market Risk, Legal Proceedings, and Risk Factors.
  • 3Investors are directed to the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" for detailed operational and financial insights.
  • 4The "Risk Factors" section (Item 1A) is crucial for understanding potential headwinds and uncertainties facing Bristol Myers Squibb.
  • 5The provided excerpt focuses on the structure and index of the 10-Q, not specific financial performance figures.
  • 6The report signifies ongoing financial reporting and regulatory compliance for Bristol Myers Squibb.
  • 7Trademark information for various products is noted as being included within the filing.

Frequently Asked Questions

The provided excerpt of the 10-Q filing focuses on the structure and index of the report and does not contain specific financial performance figures such as revenue, net income, or earnings per share. Investors must refer to the full 10-Q document, particularly the Consolidated Statements of Earnings and Comprehensive Income/(Loss) and Management's Discussion and Analysis, for detailed financial results.

The filing indicates that a "Risk Factors" section (Item 1A) is included. Investors should consult this section within the full 10-Q report to identify and understand the specific risks and uncertainties that could materially affect Bristol Myers Squibb's business, financial condition, or results of operations. These could range from regulatory challenges to market competition and operational issues.

The "Management’s Discussion and Analysis of Financial Condition and Results of Operations" (Item 2) is the primary section for investors seeking insights into the company's performance drivers, financial condition, liquidity, capital resources, and future outlook. It provides management's perspective on the financial results and trends.

The table of contents indicates a section for "Legal Proceedings" (Item 1). While the excerpt does not provide details, investors should review this section in the full 10-Q filing for information on any material legal matters that could impact the company.